122 related articles for article (PubMed ID: 29789103)
41. Development and validation of a liquid chromatography/tandem mass spectrometry procedure for the quantification of adefovir in human plasma.
Chen X; Liu D; Zhu L; Zhong D
Rapid Commun Mass Spectrom; 2005; 19(13):1893-8. PubMed ID: 15945027
[TBL] [Abstract][Full Text] [Related]
42. In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents.
Qi X; Xiong S; Yang H; Miller M; Delaney WE
Antivir Ther; 2007; 12(3):355-62. PubMed ID: 17591025
[TBL] [Abstract][Full Text] [Related]
43. Understanding adefovir pharmacokinetics as a component of a transporter phenotyping cocktail.
Dong Q; Chen C; Taubert M; Bilal M; Kinzig M; Sörgel F; Scherf-Clavel O; Fuhr U; Dokos C
Eur J Clin Pharmacol; 2024 Jul; 80(7):1069-1078. PubMed ID: 38546841
[TBL] [Abstract][Full Text] [Related]
44. Antiviral efficacy of adefovir dipivoxil versus lamivudine in patients with chronic hepatitis B sequentially treated with lamivudine and adefovir due to lamivudine resistance.
Seo YS; Kim JH; Yeon JE; Park JJ; Kim JS; Byun KS; Bak YT; Lee CH
World J Gastroenterol; 2007 Aug; 13(30):4072-9. PubMed ID: 17696224
[TBL] [Abstract][Full Text] [Related]
45. Coformer selection based on degradation pathway of drugs: a case study of adefovir dipivoxil-saccharin and adefovir dipivoxil-nicotinamide cocrystals.
Gao Y; Gao J; Liu Z; Kan H; Zu H; Sun W; Zhang J; Qian S
Int J Pharm; 2012 Nov; 438(1-2):327-35. PubMed ID: 22989978
[TBL] [Abstract][Full Text] [Related]
46. [Determination of adefovir in monkey plasma by liquid chromatography-tandem mass spectrometry].
Zhao LY; Chen XY; Zhang Y; Yang HY; Zhong DF
Yao Xue Xue Bao; 2003 Feb; 38(2):120-3. PubMed ID: 12778747
[TBL] [Abstract][Full Text] [Related]
47. Corneal permeation of ganciclovir: mechanism of ganciclovir permeation enhancement by acyl ester prodrug design.
Tirucherai GS; Dias C; Mitra AK
J Ocul Pharmacol Ther; 2002 Dec; 18(6):535-48. PubMed ID: 12537680
[TBL] [Abstract][Full Text] [Related]
48. [A clinical study of adefovir dipivoxil treatment for chronic hepatitis patients with cirrhosis in their decompensation period].
Yang Q; Gong ZJ; Hu DF
Zhonghua Gan Zang Bing Za Zhi; 2009 Jul; 17(7):515-9. PubMed ID: 19912686
[TBL] [Abstract][Full Text] [Related]
49. Functional involvement of multidrug resistance-associated protein 4 (MRP4/ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir.
Imaoka T; Kusuhara H; Adachi M; Schuetz JD; Takeuchi K; Sugiyama Y
Mol Pharmacol; 2007 Feb; 71(2):619-27. PubMed ID: 17110501
[TBL] [Abstract][Full Text] [Related]
50. [Tubular transporters OAT1 and MRP2 and clearance of adefovir].
Servais A; Lechat P; Zahr N; Urien S; Aymard G; Jaudon MC; Deray G; Isnard Bagnis C
Nephrol Ther; 2005 Nov; 1(5):296-300. PubMed ID: 16895698
[TBL] [Abstract][Full Text] [Related]
51. Systemic and renal pharmacokinetics of adefovir and tenofovir upon coadministration.
Kearney BP; Ramanathan S; Cheng AK; Ebrahimi R; Shah J
J Clin Pharmacol; 2005 Aug; 45(8):935-40. PubMed ID: 16027404
[TBL] [Abstract][Full Text] [Related]
52. Virological response and incidence of adefovir resistance in lamivudine-resistant patients treated with adefovir dipivoxil.
Chen CH; Wang JH; Lee CM; Hung CH; Hu TH; Wang JC; Lu SN; Changchien CS
Antivir Ther; 2006; 11(6):771-8. PubMed ID: 17310821
[TBL] [Abstract][Full Text] [Related]
53. Ion pair-mediated transport of metoprolol across a three lipid-component PAMPA system.
Teksin ZS; Hom K; Balakrishnan A; Polli JE
J Control Release; 2006 Nov; 116(1):50-7. PubMed ID: 17049402
[TBL] [Abstract][Full Text] [Related]
54. Enhanced dissolution and stability of adefovir dipivoxil by cocrystal formation.
Gao Y; Zu H; Zhang J
J Pharm Pharmacol; 2011 Apr; 63(4):483-90. PubMed ID: 21401599
[TBL] [Abstract][Full Text] [Related]
55. [Application and efficacy of adefovir dipivoxil in hepatitis B virus-associated chronic liver diseases].
Cho YK; Kim BI
Korean J Gastroenterol; 2003 Nov; 42(5):357-62. PubMed ID: 14646571
[TBL] [Abstract][Full Text] [Related]
56. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B.
Peters MG; Hann Hw Hw; Martin P; Heathcote EJ; Buggisch P; Rubin R; Bourliere M; Kowdley K; Trepo C; Gray Df Df; Sullivan M; Kleber K; Ebrahimi R; Xiong S; Brosgart CL
Gastroenterology; 2004 Jan; 126(1):91-101. PubMed ID: 14699491
[TBL] [Abstract][Full Text] [Related]
57. [Determination of adefovir dipivoxil and its degradation products by reversed-phase high performance liquid chromatography].
Jiang Y; Xu Z; Zhang X
Se Pu; 2004 May; 22(3):248-51. PubMed ID: 15712909
[TBL] [Abstract][Full Text] [Related]
58. Pharmacokinetics of telbivudine in healthy subjects and absence of drug interaction with lamivudine or adefovir dipivoxil.
Zhou XJ; Fielman BA; Lloyd DM; Chao GC; Brown NA
Antimicrob Agents Chemother; 2006 Jul; 50(7):2309-15. PubMed ID: 16801406
[TBL] [Abstract][Full Text] [Related]
59. Synthesis and in vivo evaluation of prodrugs of 9-[2-(phosphonomethoxy)ethoxy]adenine.
Serafinowska HT; Ashton RJ; Bailey S; Harnden MR; Jackson SM; Sutton D
J Med Chem; 1995 Apr; 38(8):1372-9. PubMed ID: 7731022
[TBL] [Abstract][Full Text] [Related]
60. [Entecavir 1.0mg monotherapy or entecavir plus adefovir dipivoxil for patients with lamivudine-resistant chronic hepatitis B had suboptimal response to lamivudine plus adefovir dipivoxil].
Xing J; Han T; Liu L; Li Y; Li J; Li Y; Xiao SX
Zhonghua Gan Zang Bing Za Zhi; 2011 Nov; 19(11):828-32. PubMed ID: 22433304
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
